We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

216 hedge funds and large institutions have $3.43B invested in Janux Therapeutics in 2024 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 80 increasing their positions, 43 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 21

233% more funds holding in top 10

Funds holding in top 10: 3 → 10 (+7)

91% more call options, than puts

Call options by funds: $37.7M | Put options by funds: $19.7M

86% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 43

66% more capital invested

Capital invested by funds: $2.07B → $3.43B (+$1.36B)

35% more funds holding

Funds holding: 160 → 216 (+56)

23.5% more ownership

Funds ownership: 87.46% → 110.97% (+24%)

Holders
216
Holders Change
+56
Holders Change %
+35%
% of All Funds
2.85%
Holding in Top 10
10
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+233.33%
% of All Funds
0.13%
New
78
Increased
80
Reduced
43
Closed
21
Calls
$37.7M
Puts
$19.7M
Net Calls
+$18M
Net Calls Change
+$43.7M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$63.5M
2
PBA
Paradigm Biocapital Advisors
New York
+$59M
3
CAM
Cormorant Asset Management
Massachusetts
+$55.5M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$55M
5
Holocene Advisors
Holocene Advisors
New York
+$53.7M

Top Sellers

1
O
OrbiMed
New York
-$26.4M
2
VPC
Vestal Point Capital
New York
-$22M
3
CS
Candriam SCA
Luxembourg
-$6.23M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$4.95M
5
State Street
State Street
Massachusetts
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
HM
226
Harvest Management
New York
– -$422K -9,300 Closed
VU
227
Valence8 US
Massachusetts
– -$357K -7,857 Closed
YIH
228
Y-Intercept (HK)
Hong Kong
– -$317K -6,971 Closed
ECM
229
ExodusPoint Capital Management
New York
– -$291K -6,413 Closed
SG Americas Securities
230
SG Americas Securities
New York
– -$261K -5,738 Closed
JGC
231
J. Goldman & Co
New York
– -$245K -5,400 Closed
CC
232
Corton Capital
Ontario, Canada
– -$234K -5,140 Closed
FC
233
FORA Capital
Florida
– -$209K -4,599 Closed
SSG
234
Summit Securities Group
New York
– -$32K -700 Closed
CPA
235
Capital Performance Advisors
California
– -$772 -17 Closed
National Bank of Canada
236
National Bank of Canada
Quebec, Canada
– -$45 -1 Closed
6 7 8 9
10

JANX Hedge Fund Activity: Q4 2024 in Review

216 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2024, worth a combined $3.43B — up 66% from $2.07B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new JANX positions and 21 closed out — a net gain of 57 holders — while 80 added to existing stakes and 43 trimmed.

The largest buyer was RA Capital Management, adding an estimated $63.5M. The largest seller was OrbiMed, cutting an estimated $26.4M.

  • 216 institutional investors held Janux Therapeutics (JANX) as of Q4 2024, up from 160 in Q3 2024.
  • Funds reported $3.43B of Janux Therapeutics stock for Q4 2024, up 66% quarter-over-quarter.
  • 78 funds opened new Janux Therapeutics positions in Q4 2024 and 21 closed out, a net change of +57 holders.
  • The largest Janux Therapeutics buyer in Q4 2024 was RA Capital Management, an estimated $63.5M added.
  • The largest Janux Therapeutics seller in Q4 2024 was OrbiMed, an estimated $26.4M sold.

Based on aggregated 13F filings for Q4 2024.